Applied Therapeutics (NASDAQ:APLT) Issues Quarterly Earnings Results, Misses Expectations by $0.05 EPS
Applied Therapeutics (NASDAQ:APLT – Get Rating) issued its quarterly earnings results on Thursday. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.05), MarketWatch Earnings reports.
Shares of NASDAQ:APLT opened at $1.72 on Friday. Applied Therapeutics has a 12 month low of $1.45 and a 12 month high of $25.59. The company has a 50-day moving average price of $2.00 and a 200 day moving average price of $5.44.
In related news, insider Riccardo Perfetti bought 30,000 shares of Applied Therapeutics stock in a transaction dated Wednesday, March 23rd. The shares were acquired at an average cost of $1.97 per share, with a total value of $59,100.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 27.20% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of APLT. Royal Bank of Canada boosted its stake in shares of Applied Therapeutics by 77.3% in the third quarter. Royal Bank of Canada now owns 2,151 shares of the company’s stock worth $36,000 after buying an additional 938 shares during the last quarter. BNP Paribas Arbitrage SA increased its holdings in shares of Applied Therapeutics by 308.2% in the third quarter. BNP Paribas Arbitrage SA now owns 3,135 shares of the company’s stock valued at $52,000 after purchasing an additional 2,367 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Applied Therapeutics in the third quarter valued at approximately $67,000. Wells Fargo & Company MN increased its holdings in shares of Applied Therapeutics by 385,900.0% in the fourth quarter. Wells Fargo & Company MN now owns 7,720 shares of the company’s stock valued at $69,000 after purchasing an additional 7,718 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in Applied Therapeutics during the first quarter worth $70,000. Institutional investors and hedge funds own 95.51% of the company’s stock.
A number of brokerages recently issued reports on APLT. Barclays reduced their price target on Applied Therapeutics from $7.00 to $2.50 and set an “equal weight” rating on the stock in a report on Monday, March 21st. Zacks Investment Research raised Applied Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research report on Wednesday, March 2nd. Finally, Truist Financial dropped their price target on Applied Therapeutics to $6.00 in a research report on Wednesday, April 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $12.08.
About Applied Therapeutics (Get Rating)
Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG.
- Get a free copy of the StockNews.com research report on Applied Therapeutics (APLT)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded